SLC5A2 and type 2 diabetes mellitus: The exception was for people with type 3c diabetes and PEI, who had greater mean weight loss on SGLT2‐inhibitors compared to T2D controls (1.4 [95% CI 0.6–2.3] kg greater weight loss) and lesser mean weight gain on sulphonylureas (1.1 [95% CI 0.7–1.5] kg lesser weight gain).